Five Things Big Pharma—And Its Investors—Could Learn From Synthetic Biology Drug discovery is becoming slower and more expensive over time, despite better, cheaper tools in technology and biology. Can COVID shake pharma from its inertia? Can synthetic biology save drug makers?